187 related articles for article (PubMed ID: 38017026)
1. Generation of "OP7 chimera" defective interfering influenza A particle preparations free of infectious virus that show antiviral efficacy in mice.
Dogra T; Pelz L; Boehme JD; Kuechler J; Kershaw O; Marichal-Gallardo P; Baelkner M; Hein MD; Gruber AD; Benndorf D; Genzel Y; Bruder D; Kupke SY; Reichl U
Sci Rep; 2023 Nov; 13(1):20936. PubMed ID: 38017026
[TBL] [Abstract][Full Text] [Related]
2. Production of antiviral "OP7 chimera" defective interfering particles free of infectious virus.
Pelz L; Dogra T; Marichal-Gallardo P; Hein MD; Hemissi G; Kupke SY; Genzel Y; Reichl U
Appl Microbiol Biotechnol; 2024 Dec; 108(1):97. PubMed ID: 38229300
[TBL] [Abstract][Full Text] [Related]
3. A Novel Type of Influenza A Virus-Derived Defective Interfering Particle with Nucleotide Substitutions in Its Genome.
Kupke SY; Riedel D; Frensing T; Zmora P; Reichl U
J Virol; 2019 Feb; 93(4):. PubMed ID: 30463972
[TBL] [Abstract][Full Text] [Related]
4. Cell culture-based production and in vivo characterization of purely clonal defective interfering influenza virus particles.
Hein MD; Arora P; Marichal-Gallardo P; Winkler M; Genzel Y; Pöhlmann S; Schughart K; Kupke SY; Reichl U
BMC Biol; 2021 May; 19(1):91. PubMed ID: 33941189
[TBL] [Abstract][Full Text] [Related]
5. Semi-continuous Propagation of Influenza A Virus and Its Defective Interfering Particles: Analyzing the Dynamic Competition To Select Candidates for Antiviral Therapy.
Pelz L; Rüdiger D; Dogra T; Alnaji FG; Genzel Y; Brooke CB; Kupke SY; Reichl U
J Virol; 2021 Nov; 95(24):e0117421. PubMed ID: 34550771
[TBL] [Abstract][Full Text] [Related]
6. OP7, a novel influenza A virus defective interfering particle: production, purification, and animal experiments demonstrating antiviral potential.
Hein MD; Kollmus H; Marichal-Gallardo P; Püttker S; Benndorf D; Genzel Y; Schughart K; Kupke SY; Reichl U
Appl Microbiol Biotechnol; 2021 Jan; 105(1):129-146. PubMed ID: 33275160
[TBL] [Abstract][Full Text] [Related]
7. Broad-Spectrum Antiviral Activity of Influenza A Defective Interfering Particles against Respiratory Syncytial, Yellow Fever, and Zika Virus Replication In Vitro.
Pelz L; Piagnani E; Marsall P; Wynserski N; Hein MD; Marichal-Gallardo P; Kupke SY; Reichl U
Viruses; 2023 Sep; 15(9):. PubMed ID: 37766278
[TBL] [Abstract][Full Text] [Related]
8. Antiviral Activity of Influenza A Virus Defective Interfering Particles against SARS-CoV-2 Replication In Vitro through Stimulation of Innate Immunity.
Rand U; Kupke SY; Shkarlet H; Hein MD; Hirsch T; Marichal-Gallardo P; Cicin-Sain L; Reichl U; Bruder D
Cells; 2021 Jul; 10(7):. PubMed ID: 34359926
[TBL] [Abstract][Full Text] [Related]
9. Multiscale model of defective interfering particle replication for influenza A virus infection in animal cell culture.
Rüdiger D; Pelz L; Hein MD; Kupke SY; Reichl U
PLoS Comput Biol; 2021 Sep; 17(9):e1009357. PubMed ID: 34491996
[TBL] [Abstract][Full Text] [Related]
10. Mathematical model calibrated to
Rüdiger D; Piasecka J; Küchler J; Pontes C; Laske T; Kupke SY; Reichl U
iScience; 2024 Apr; 27(4):109421. PubMed ID: 38523782
[TBL] [Abstract][Full Text] [Related]
11. Cell culture-based production of defective interfering particles for influenza antiviral therapy.
Wasik MA; Eichwald L; Genzel Y; Reichl U
Appl Microbiol Biotechnol; 2018 Feb; 102(3):1167-1177. PubMed ID: 29204901
[TBL] [Abstract][Full Text] [Related]
12. Evidence that two instead of one defective interfering RNA in influenza A virus-derived defective interfering particles (DIPs) does not enhance antiviral activity.
Bdeir N; Arora P; Gärtner S; Pöhlmann S; Winkler M
Sci Rep; 2021 Oct; 11(1):20477. PubMed ID: 34650149
[TBL] [Abstract][Full Text] [Related]
13. A system for production of defective interfering particles in the absence of infectious influenza A virus.
Bdeir N; Arora P; Gärtner S; Hoffmann M; Reichl U; Pöhlmann S; Winkler M
PLoS One; 2019; 14(3):e0212757. PubMed ID: 30822349
[TBL] [Abstract][Full Text] [Related]
14. Impact of defective interfering particles on virus replication and antiviral host response in cell culture-based influenza vaccine production.
Frensing T; Pflugmacher A; Bachmann M; Peschel B; Reichl U
Appl Microbiol Biotechnol; 2014 Nov; 98(21):8999-9008. PubMed ID: 25132064
[TBL] [Abstract][Full Text] [Related]
15. Cell culture-based production of defective interfering influenza A virus particles in perfusion mode using an alternating tangential flow filtration system.
Hein MD; Chawla A; Cattaneo M; Kupke SY; Genzel Y; Reichl U
Appl Microbiol Biotechnol; 2021 Oct; 105(19):7251-7264. PubMed ID: 34519855
[TBL] [Abstract][Full Text] [Related]
16. Sequencing Framework for the Sensitive Detection and Precise Mapping of Defective Interfering Particle-Associated Deletions across Influenza A and B Viruses.
Alnaji FG; Holmes JR; Rendon G; Vera JC; Fields CJ; Martin BE; Brooke CB
J Virol; 2019 Jun; 93(11):. PubMed ID: 30867305
[TBL] [Abstract][Full Text] [Related]
17. Modeling the intracellular replication of influenza A virus in the presence of defective interfering RNAs.
Laske T; Heldt FS; Hoffmann H; Frensing T; Reichl U
Virus Res; 2016 Feb; 213():90-99. PubMed ID: 26592173
[TBL] [Abstract][Full Text] [Related]
18. (In)validating experimentally derived knowledge about influenza A defective interfering particles.
Liao LE; Iwami S; Beauchemin CA
J R Soc Interface; 2016 Nov; 13(124):. PubMed ID: 27881801
[TBL] [Abstract][Full Text] [Related]
19. Influenza A Virus Defective Viral Genomes Are Inefficiently Packaged into Virions Relative to Wild-Type Genomic RNAs.
Alnaji FG; Reiser WK; Rivera-Cardona J; Te Velthuis AJW; Brooke CB
mBio; 2021 Dec; 12(6):e0295921. PubMed ID: 34809454
[TBL] [Abstract][Full Text] [Related]
20. Production of Defective Interfering Particles of Influenza A Virus in Parallel Continuous Cultures at Two Residence Times-Insights From qPCR Measurements and Viral Dynamics Modeling.
Tapia F; Laske T; Wasik MA; Rammhold M; Genzel Y; Reichl U
Front Bioeng Biotechnol; 2019; 7():275. PubMed ID: 31681751
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
